USPTO serial 90532969
PILLAR BIOSCIENCES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 28, 2023
- Examiner
- CLYBURN, CARLA DIONNE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PILLAR BIOSCIENCES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew T. Pettit
Andrew T. Pettit PERKINS COIE LLPP.O. BOX 2608Seattle, WA 98111UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents and reagent kits comprising nucleic acids, naturally occurring and modified nucleotides, enzymes, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulations, transcriptions, and expressions, with the aforementioned reagents and reagent kits being in the fields of scientific research, clinical research, and scientific diagnostics research; biological and biochemical reagents and reagent kits for selectively amplifying nucleic acid fragments for scientific research, clinical research, and scientific diagnostics research; biological and biochemical kits for scientific research, clinical research, and scientific diagnostics research | ACTIVE | Sep 15, 2021 |
| 005 | Reagents and reagent kits comprising nucleic acids, naturally occurring and modified nucleotides, enzymes, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulations, transcriptions, and expressions, with the aforementioned reagents and reagent kits being for medical diagnostic purposes; biological and biochemical reagents and reagent kits for selectively amplifying nucleic acid fragments for medical diagnostic purposes; biological and biochemical kits comprised of diagnostic preparations for medical purposes, namely, for the diagnosis and treatment of cancer; biological and biochemical kits for medical diagnostic purposes | ACTIVE | Sep 15, 2021 |
| 009 | Downloadable computer software for the collection, management, and analysis of data for use in the fields of scientific research, clinical research, scientific diagnostics, and medical diagnostics; downloadable computer software for analyzing biological samples; downloadable computer software for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; downloadable computer software for use with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, scientific diagnostics research, and medical diagnostics; downloadable computer software for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; downloadable computer software for health and wellness assessment, namely, for use in genomic analysis; downloadable computer software for genetic and bioinformatics analysis | ACTIVE | Sep 15, 2021 |
| 035 | Data processing services for medical, clinical, and scientific purposes | ACTIVE | Sep 15, 2021 |
| 042 | Software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for collecting, managing, and analyzing data in the fields of scientific research, clinical research, scientific diagnostics, and medical diagnostics; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others with reagents and reagent kits, all for the purpose of detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, scientific diagnostics research, and medical diagnostics; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; software as a service (SaaS), namely, hosting non-downloadable computer software for health and wellness assessment, namely, for genomic analysis; software as a service (SaaS), namely, hosting non-downloadable computer software for genetic and bioinformatics analysis; bioinformatics services, namely, product research and development in the field of bioinformatics; developing diagnostic testing models for others for medical, clinical, and scientific purposes; genetic testing for scientific research purposes; scientific research consulting | ACTIVE | Sep 15, 2021 |
| 044 | Providing biological sample testing services for others in the field of medical diagnostics; providing biological sample testing services for others for medical purposes, namely, for the diagnosis and treatment of cancer; providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the field of medical diagnostics; medical testing for diagnostic and treatment purposes; health and wellness assessment services; providing health and wellness information | ACTIVE | Sep 15, 2021 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Pillar Biosciences, Inc.
- Other trademarks owned by Pillar Biosciences, Inc.
- Other trademarks owned by Pillar Biosciences, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PILLAR BIOSCIENCES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 28, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 28, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 27, 2023 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jan 26, 2023 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jan 20, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 19, 2023 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 19, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 19, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 4, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 4, 2023 | IUAF | USE AMENDMENT FILED | — |
| Jan 4, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 4, 2023 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Oct 27, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 27, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Oct 27, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 27, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 5, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 10, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 10, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 20, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 7, 2022 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 4, 2022 | ALIE | ASSIGNED TO LIE | — |
| Mar 31, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 22, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 21, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 21, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 21, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 21, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| May 19, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 23, 2021 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Feb 23, 2021 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 20, 2021 | NWAP | NEW APPLICATION ENTERED | — |